BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31515354)

  • 1. Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism.
    Mazzarella L; Botteri E; Matthews A; Gatti E; Di Salvatore D; Bagnardi V; Breccia M; Montesinos P; Bernal T; Gil C; Ley TJ; Sanz M; Bhaskaran K; Coco FL; Pelicci PG
    Haematologica; 2020 Jun; 105(6):1559-1566. PubMed ID: 31515354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytogenetic and FMS-like tyrosine kinase 3 mutation analyses in acute promyelocytic leukemia patients.
    Yaghmaie M; Alimoghaddam K; Mozdarani H; Ghavamzadeh A; Hajhashemi M; Aznab M; Ghaffari SH
    Iran Biomed J; 2012; 16(1):10-7. PubMed ID: 22562027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
    Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
    Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanopore sequencing sheds a light on the
    Cumbo C; Orsini P; Anelli L; Zagaria A; Minervini CF; Coccaro N; Tota G; Impera L; Parciante E; Conserva MR; Redavid I; Carluccio P; Tarantini F; Specchia G; Musto P; Albano F
    Leuk Lymphoma; 2021 May; 62(5):1219-1225. PubMed ID: 33289421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.
    Barragán E; Montesinos P; Camos M; González M; Calasanz MJ; Román-Gómez J; Gómez-Casares MT; Ayala R; López J; Fuster Ó; Colomer D; Chillón C; Larrayoz MJ; Sánchez-Godoy P; González-Campos J; Manso F; Amador ML; Vellenga E; Lowenberg B; Sanz MA; ;
    Haematologica; 2011 Oct; 96(10):1470-7. PubMed ID: 21685470
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Esnault C; Rahmé R; Rice KL; Berthier C; Gaillard C; Quentin S; Maubert AL; Kogan S; de Thé H
    Blood; 2019 Mar; 133(13):1495-1506. PubMed ID: 30674471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.
    Sohal J; Phan VT; Chan PV; Davis EM; Patel B; Kelly LM; Abrams TJ; O'Farrell AM; Gilliland DG; Le Beau MM; Kogan SC
    Blood; 2003 Apr; 101(8):3188-97. PubMed ID: 12515727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between FLT3-ITD status and clinical, cellular and molecular profiles in promyelocytic acute leukemias.
    Souza Melo CP; Campos CB; Dutra ÁP; Neto JC; Fenelon AJ; Neto AH; Carbone EK; Pianovski MA; Ferreira AC; Assumpcão JG
    Leuk Res; 2015 Feb; 39(2):131-7. PubMed ID: 25530565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
    Poiré X; Moser BK; Gallagher RE; Laumann K; Bloomfield CD; Powell BL; Koval G; Gulati K; Holowka N; Larson RA; Tallman MS; Appelbaum FR; Sher D; Willman C; Paietta E; Stock W
    Leuk Lymphoma; 2014 Jul; 55(7):1523-32. PubMed ID: 24160850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [FLT3 mutation in acute promyelocytic leukemia patients with extramedullary relapse].
    Liu J; Zou XL; Liu TT; Jiang M; Niu T
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):670-4. PubMed ID: 25286697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevalence and clinical significance of FLT3 mutations in acute promyelocytic leukemia].
    Xue MX; Qiu HY; Feng YF; Zhu ZL; Chang WR; Liang JY; Chen SN; Cen JN; Xue YQ; Liu YJ; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):757-61. PubMed ID: 19176014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inferior prognostic outcome in acute promyelocytic leukemia with alterations of FLT3 gene.
    Yoo SJ; Park CJ; Jang S; Seo EJ; Lee KH; Chi HS
    Leuk Lymphoma; 2006 Sep; 47(9):1788-93. PubMed ID: 17064989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status.
    Xu LW; Su YZ; Tao HF
    Curr Med Sci; 2021 Jun; 41(3):491-497. PubMed ID: 34169421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of CD2, CD4, and HLA-DR expression and FLT3-ITD mutation in adult acute promyelocytic leukemia.
    Nie L; Ma R; Yuan X; Jiang L; Yang S; Xu H; Liu X; Liu Y; Zhang L; Zhu Z
    Leuk Lymphoma; 2020 Oct; 61(10):2482-2487. PubMed ID: 32476519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia.
    Shih LY; Kuo MC; Liang DC; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Lai CL
    Cancer; 2003 Sep; 98(6):1206-16. PubMed ID: 12973844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
    Callens C; Chevret S; Cayuela JM; Cassinat B; Raffoux E; de Botton S; Thomas X; Guerci A; Fegueux N; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Ferrand A; Sanz M; Chomienne C; Fenaux P; Dombret H;
    Leukemia; 2005 Jul; 19(7):1153-60. PubMed ID: 15889156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.
    Schnittger S; Bacher U; Haferlach C; Kern W; Alpermann T; Haferlach T
    Haematologica; 2011 Dec; 96(12):1799-807. PubMed ID: 21859732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical significance of common leukemia gene mutations in patients with acute promyelocytic leukemia].
    Yin J; Sun AN; Tian XP; Tian H; Wang RX; Yang Z; Wang XL; Wu DP; Qiu HY; Pan JL; Cen JN; Liang JY; Chen SN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):39-44. PubMed ID: 23484688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3 overexpression in acute promyelocytic leukemia patients without detectable FLT3-ITD or codon 835-836 mutations: a pilot study.
    Lilakos K; Viniou NA; Mavrogianni D; Vassilakopoulos TP; Dimopoulou MN; Plata E; Angelopoulou MK; Variami E; Stavrogianni N; Liapi D; Xilouri I; Galanopoulos A; Ageloudi M; Panayiotidis P; Voulgarelis M; Rombos J; Meletis J; Yataganas X; Pangalis GA
    Anticancer Res; 2006; 26(2A):1201-7. PubMed ID: 16619525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical significance of FLT3 ITD mutation on the prognosis of adult acute promyelocytic leukemia.
    Fan Y; Cao Y; Bai X; Zhuang W
    Hematology; 2018 Aug; 23(7):379-384. PubMed ID: 29251252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.